Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers

Journal of Clinical Pharmacology

Volumn 51, Issue 7, 2011, Pages 1079-1086

  Nishino, Masafumi ^a   Sugimoto, Mitsushige ^b   Kodaira, Chise ^a   Yamade, Mihoko ^a   Uotani, Takahiro ^a   Shirai, Naohito ^d   Ikuma, Mutsuhiro ^a   Tanaka, Tatsuo ^c   Sugimura, Haruhiko ^b   Hishida, Akira ^a   Furuta, Takahisa ^b  

^a First Department of Medicine   (Japan)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Department of Photodynamic and Endoscopic Medicine ^*  (Japan)

^d JA Shizuoka Kohseiren Enshu Hospital   (Japan)

Author keywords

Aspirin; CYP2C19; H2 receptor antagonist; NSAIDs; proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450 2C19; FAMOTIDINE; LANSOPRAZOLE;

ADULT; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DNA POLYMORPHISM; FEMALE; GASTROSCOPY; GENOTYPE; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; JAPANESE; MALE; NORMAL HUMAN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH MUCOSA INJURY; STOMACH PH;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASPIRIN; CROSS-OVER STUDIES; FAMOTIDINE; FEMALE; GASTRIC ACIDITY DETERMINATION; GASTRIC MUCOSA; GENOTYPE; HISTAMINE H2 ANTAGONISTS; HUMANS; JAPAN; MALE; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; STOMACH ULCER; YOUNG ADULT;

EID: 79958813872     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010376194     Document Type: Article

References (34)

1. Nishikawa K, Sugiyama T, Kato M, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol. 2000 ; 12: 635-640 (Pubitemid 30433538)
2. Tkachenko MA, Zhannat NZ, Erman LV, et al. Dramatic changes in the prevalence of Helicobacter pylori infection during childhood: a 10-year follow-up study in Russia. J Pediatr Gastroenterol Nutr. 2007 ; 45: 428-432 (Pubitemid 350307160)
3. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter. 2007 ; 12: 333-340 (Pubitemid 47196330)
4. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000 ; 101: 1206-1218 (Pubitemid 30146625)
5. Taha AS, Angerson WJ, Knill-Jones RP, Blatchford O. Upper gastrointestinal haemorrhage associated with low-dose aspirin and anti-thrombotic drugs-a 6-year analysis and comparison with non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2005 ; 22: 285-289 (Pubitemid 41207457)
6. Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005 ; 22: 795-801 (Pubitemid 41564359)
7. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000 ; 321: 1183-1187
8. Pilotto A, Franceschi M, Leandro G, et al. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2004 ; 20: 1091-1097 (Pubitemid 39657942)
9. Serrano P, Lanas A, Arroyo MT, Ferreira IJ. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002 ; 16: 1945-1953
10. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002 ; 162: 169-175 (Pubitemid 34098186)
11. Taha AS, McCloskey C, Prasad R, Bezlyak V. Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 119-125
12. Nakashima S, Ota S, Arai S, et al. Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J Gastroenterol. 2009 ; 15: 727-731
13. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther. 1999 ; 13 (suppl 3). 27-36 (Pubitemid 29389409)
14. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther. 1999 ; 65: 552-561 (Pubitemid 29237329)
15. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001 ; 15: 1929-1937 (Pubitemid 34014349)
16. Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics. 2004 ; 5: 181-202 (Pubitemid 38351277)
17. Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther. 2006 ; 79: 144-152 (Pubitemid 43069585)
18. Shirai N, Furuta T, Xiao F, et al. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups. Aliment Pharmacol Ther. 2002 ; 16: 837-846 (Pubitemid 34407534)
19. Nishino M, Sugimoto M, Kodaira C, et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci. 2010 ; 55: 1627-1636
20. Sugimoto M, Nishino M, Kodaira C, et al. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J Clin Pharmacol. 2010 ; 50: 320-330
21. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 ; 46: 594-598 (Pubitemid 24334747)
22. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 ; 269: 15419-15422
23. Lanza FL, Royer GL, Nelson RS, Chen TT, Seckman CE, Rack MF. A comparative endoscopic evaluation of the damaging effects of nonsteroidal anti-inflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol. 1981 ; 75: 17-21 (Pubitemid 11106121)
24. Naito Y, Yoshikawa T, Iinuma S, et al. Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study. Dig Dis Sci. 1998 ; 43 (9 suppl). 83S - 89S (Pubitemid 28433955)
25. Elliott SL, Ferris RJ, Giraud AS, Cook GA, Skeljo MV, Yeomans ND. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol. 1996 ; 23: 432-434 (Pubitemid 26171549)
26. Funatsu T, Chono K, Hirata T, Keto Y, Kimoto A, Sasamata M. Mucosal acid causes gastric mucosal microcirculatory disturbance in nonsteroidal anti-inflammatory drug-treated rats. Eur J Pharmacol. 2007 ; 554: 53-59 (Pubitemid 44820047)
27. Kitahora T, Guth PH. Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. Gastroenterology. 1987 ; 93: 810-817 (Pubitemid 17156007)
28. Shiotani A, Sakakibara T, Yamanaka Y, et al. The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy. J Gastroenterol. 2009 ; 44: 717-725
29. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007 ; 102: 507-515 (Pubitemid 46328156)
30. Niazi M, Andersson T, Naucler E, Sundin M, Naesdal J. Evaluation of the pharmacokinetic interaction between esomeprazole (40 mg) and acetylsalicylic acid (325 mg) in healthy volunteers. Int J Clin Pharmacol Ther. 2009 ; 47: 564-569
31. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation: a randomized crossover study. J Cardiovasc Pharmacol. 2009 ; 54: 163-168
32. Nefesoglu FZ, Ayanoglu-Dulger G, Ulusoy NB, Imeryuz N. Interaction of omeprazole with enteric-coated salicylate tablets. Int J Clin Pharmacol Ther. 1998 ; 36: 549-553 (Pubitemid 28468232)
33. Lev EI, Ramabadran RS, Guthikonda S, et al. Effect of ranitidine on the antiplatelet effects of aspirin in healthy human subjects. Am J Cardiol. 2007 ; 99: 124-128 (Pubitemid 44969352)
34. Wurtz M, Grove EL, Kristensen SD, Hvas AM. The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease. Heart. 2010 ; 96: 368-371